'김갑성' 기자의 전체기사
-
New Regional Certifications to Boost Healthcare Training Stan…
Two new specially designed certification programmes will train doctors, nurses and technical specialists across the region in simulation-based medical education. SINGAPORE, Nov. 6, 2025 -- The first healthcare simulation certification programmes designed specifically for Southeast Asian professionals were launched at the S3 Conference 2025 opening ceremony today. The event was attended by Mr Tan Kiat How, Senior Minister of State, Ministry of Digital Development and Information & Ministry of Health. The Certified Educator in Healthcare Simulation (CEHS) and Certified T
- 김갑성 기자
- 2025-11-06 10:13
-
Ispire Technology Inc.、2026年度第1四半期決算電話会議の開催を予定
ロサンゼルス, 2025年11月6日 -- 電子タバコ技術と精密投与の先駆者であるIspire Technology Inc.（以下「Ispire」または「同社」）（NASDAQ：ISPR）は本日、2025年9月30日に終了した第1四半期の決算結果について説明するため、2025年11月6日（木曜）午前8時（米国東部時間）より決算電話会議を開催することを発表しました。 決算電話会議を聞くには、下記の番号でダイヤル・インしてください。ダイヤル・イン時に案内があった場合は、「Ispire Technology Call」とお申し出ください。 開催日：2025年11月6日（木曜） 時間：午前8時 中央ヨーロッパ時間（ET） ダイヤル・イン番号：米国内からは 844-826-3033、海外からは +1-412-317-5185 におかけください。 この電話会議はウェブキャストでライブ配信され、関係者全員が以下からアクセスできます：https://viavid.webcasts.com/starthere.jsp?ei=1738889&tp_key=82f919c8ba。 通話開始の少なくとも15分前までにリンクにアクセスして登録の上、必要なオーディオ・ソフトウェアをダウンロード、インストールしてください。&n
- 김갑성 기자
- 2025-11-06 09:54
-
The World's First Gene-Editing Therapy Targeting APOC3 for Hy…
[ 메디채널 김갑성 기자 ] CorrectSequence Therapeutics' CS-121 Completed Dosing of First Chylomicronemia Patient, Demonstrating Excellent Safety and Significant Efficacy SHANGHAI, Nov. 6, 2025 -- On November 6, 2025, Shanghai, China, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, announced that the first patient in its Investigator-Initiated Trial (IIT) of the base-editing therapy CS-121 targeting APOC3 for chylomicronemia / hypertriglyceridemia has successful
- 김갑성 기자
- 2025-11-06 08:00
-
Natural Field will Launch "Ashwagandha White Paper" at FTA F…
HANGZHOU, China, Nov. 5, 2025 -- Natural Field, a leading Chinese supplier of botanical and functional ingredients, is set to release its highly anticipated Ashwagandha White Paper at the prestigious Food Technology and Application (FTA) Forum in Hangzhou. The forum, recognized as one of China's foremost platforms for nutrition and health innovation, brings together leading researchers, industry professionals, and enterprise executives to explore cutting-edge technological advances and market trends. Mr. Haiying Yang, founder of Natural Field, will deliver a keynote address highlightin
- 김갑성 기자
- 2025-11-05 23:00
-
Andor Health's Agentic AI Platform, ThinkAndor®, Receives Fro…
[ 메디채널 김갑성 기자 ] Recognized for its transformational innovation and customer impact in driving the evolution of acute care virtual health through advanced, agentic AI-powered collaboration solutions. SAN ANTONIO, Nov. 5, 2025 -- Frost & Sullivan is pleased to announce that Andor Health has received the 2025 North American Transformational Innovation Leadership Recognition in the acute care virtual health industry for its outstanding achievements in transformational innovation and customer impact. This recognition highlights Andor Health's consistent leadership in driving measurabl
- 김갑성 기자
- 2025-11-05 22:30
-
Milliken & Company Recognized with 2025 EcoVadis Gold Ratin…
SPARTANBURG, S.C., Nov. 5, 2025 -- Milliken & Company, a global leader in manufacturing and material science, has earned a gold rating in the 2025 EcoVadis assessment for the fourth consecutive year, placing the company among the top 5% of more than 150,000 organizations evaluated around the world. This achievement marks another milestone in Milliken's ongoing commitment to sustainability, ethical business practices and innovation. "We are proud to have earned a gold rating from EcoVadis for the fourth consecutive year," said Halsey Cook, president and CEO
- 김갑성 기자
- 2025-11-05 21:50
-
BioDlink Congratulates Lepu Biopharma on Securing Approv…
BioDlink helps Lepu Biopharma win China's marketing approval for EGFR-targeted ADC treating recurrent or metastatic nasopharyngeal carcinoma This Becotatug Vedotin injection approval is BioDlink's first commercial ADC manufacturing initiative worldwide, validating its complex biologics commercialization capabilities SUZHOU, China, Nov. 5, 2025 -- BioDlink (1875.HK) congratulates its partner Lepu Biopharma (2157.HK) on receiving conditional marketing approval from China's National Medical Products Administration (NMPA) for MEIYOUHENG (Becotatug Vedotin injection). This Cl
- 김갑성 기자
- 2025-11-05 21:00
-
IDT Biologika Accelerates Global CDMO Expansion Manufactu…
Showcased end-to-end, customized manufacturing capabilities covering vaccines, gene and immune therapeutics Strengthening global CDMO strategy through strategic synergy with SK bioscience Sustainable growth expected, backed by European commercial manufacturing infrastructure and regulatory expertise FRANKFURT, Germany, VIENNA and SEONGNAM, South Korea, Nov. 5, 2025 -- IDT Biologika GmbH (IDT), the European subsidiary of SK bioscience, has embarked on a full-scale drive to expand its global contract development and manufacturing (CDMO) business in vaccines and biopharma
- 김갑성 기자
- 2025-11-05 21:00
-
Nona Biosciences Announces Expansion of Collaboratio…
CAMBRIDGE, Mass., Nov. 5, 2025 -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I™), today announced an evaluation and license agreement with Umoja Biopharma ("Umoja"), the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR-T cells. This agreement represents an expansion of the strategic collaboration established between the two companies in September 2024. The expanded partnership aims to create multiple in vivo CAR-T cell products by
- 김갑성 기자
- 2025-11-05 20:07
-
HanchorBio Presents Preclinical Data on HCB301 at SITC 2025
[ 메디채널 김갑성 기자 ] HCB301 is a first-in-class tri-specific immunotherapy targeting SIRPα-CD47, PD-1/PD-L1, and TGFβ; it shows potent macrophage activation, T-cell restoration, and tumor microenvironment remodeling in preclinical solid tumor models. TAIPEI, SHANGHAI, and SAN FRANCISCO, Nov. 5, 2025 -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that the preclinical data on HCB301, a novel tri-specific immunotherapeutic fusion protein, has been accepted for prese
- 김갑성 기자
- 2025-11-05 20:00
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-12-10_WED
- DAR GLOBAL AWARDS ENABLING WORKS CONTRACT FOR TRUMP INTERNATIONAL HOTEL & TOWER, DUBAI TO EDRAFOR EMIRATES LLC 19:46
- Indonesia Must Accelerate Targeted Digital Investment to Move into APAC's Leading Tier of Digital Nations, says GSMA 19:42
- Yupp Video Services Powers Chaupal's Full-Scale Technology Upgrade, Strengthening Platform Reliability, Performance, and User Experience Across 25+ Devices 19:35
- CNFINANCE ANNOUNCES THE RESULTS OF ITS EXTRAORDINARY GENERAL MEETING 19:15
- 資本の首都から、ADFWが資産運用の次なるフロンティアを描く 18:58
- 이제 유니온페이 카드로 15개 국가에서 애플 서비스 온라인 결제 가능 18:46
- World Gym Corporation (2762.TW) Reports Robust November Revenue Growth and Unveils Ambitious 2026 Strategic Roadmap 18:30
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 12월 10일 21시 20분